Zibelman M - Search Results

1

Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.

Zibelman M, Ramamurthy C, Plimack ER. Zibelman M, et al. Urol Oncol. 2016 Dec;34(12):538-547. doi: 10.1016/j.urolonc.2016.10.017. Urol Oncol. 2016. PMID: 27888981 Review.

2

A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite.

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. Zibelman M, et al. Clin Genitourin Cancer. 2015 Apr;13(2):142-9. doi: 10.1016/j.clgc.2014.08.005. Epub 2014 Sep 28. Clin Genitourin Cancer. 2015. PMID: 25450029 Review.

3

Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.

Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Godwin JL, et al. Among authors: zibelman m. Discov Med. 2014 Dec;18(101):341-50. Discov Med. 2014. PMID: 25549705 Free article. Review.

4

Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.

Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Zibelman M, et al. Invest New Drugs. 2015 Oct;33(5):1040-7. doi: 10.1007/s10637-015-0261-3. Epub 2015 Jun 20. Invest New Drugs. 2015. PMID: 26091915 Free PMC article. Clinical Trial.

5

Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm.

Zibelman M, Plimack ER. Zibelman M, et al. Oncology (Williston Park). 2016 Feb;30(2):160-2, 176. Oncology (Williston Park). 2016. PMID: 26888793 Free article. No abstract available.

6

Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Zibelman M, Mehra R. Zibelman M, et al. Am J Clin Oncol. 2016 Aug;39(4):396-406. doi: 10.1097/COC.0000000000000283. Am J Clin Oncol. 2016. PMID: 26967327 Review.

7

Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?

Geynisman DM, Plimack ER, Zibelman M. Geynisman DM, et al. Among authors: zibelman m. Eur Urol. 2016 Dec;70(6):971-973. doi: 10.1016/j.eururo.2016.05.026. Epub 2016 May 26. Eur Urol. 2016. PMID: 27238654 No abstract available.

8

Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.

Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Zibelman M, et al. Immunotherapy. 2016 Jun;8(7):785-98. doi: 10.2217/imt-2016-0028. Immunotherapy. 2016. PMID: 27349978 Free PMC article. Review.

9

Systemic therapy for bladder cancer finally comes into a new age.

Zibelman M, Plimack ER. Zibelman M, et al. Future Oncol. 2016 Oct;12(19):2227-42. doi: 10.2217/fon-2016-0135. Epub 2016 Jul 12. Future Oncol. 2016. PMID: 27402371 Free PMC article. Review.

10

TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.

Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, Plimack E, Mehra R, Golemis EA, Bilusic M, Zibelman M, Elliott A. Gray PN, et al. Among authors: zibelman m. Oncotarget. 2016 Oct 18;7(42):68206-68228. doi: 10.18632/oncotarget.11910. Oncotarget. 2016. PMID: 27626691 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters